We are please to report that AbilityMate has won the 2017 National Disability Excellence in Innovation Award “We’re living in an era of design where human invention, empowered by technology… read more →
Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain… read more →
Mobius Medical, like many other CROs all over the world, is privileged to be involved in the development of a myriad of novel innovations, and life changing medical devices, diagnostic… read more →
Since the GCP (E6 R1) was first released in 1996, clinical trials have evolved substantially in complexity, technological capabilities, and costs. ICH E6(R1) has been amended to encourage implementation of… read more →
For many years, Australia has been the one of the most attractive countries to perform clinical investigations for medical devices, pharmaceuticals and in-vitro diagnostics. The Clinical Notification Scheme (CTN) is… read more →
Back pain – almost all of us has either had it or will experience it in our life time. In fact, four million Australians may be suffering from low back… read more →
Mobius is delighted by the news of Prof. Gordian Fulde being named Senior Australian of the Year this week. Suzanne, one of the Principals of Mobius Medical has had the… read more →
Mobius Medical spends a great deal of time and business development dollars informing our Northern Hemisphere colleagues of some reasons to come to Australia to conduct trials. We are CRO… read more →
The Australian government (NHMRC, the Department of Health and the Department of Industry, Innovation and Science) are constantly working to improve the clinical trial environment in Australia. Some of the… read more →
The Australian clinical trial regulatory process reduces the time to site initiation, by ONLY requiring ethics committee/clinical site approval, followed by a notification to Therapeutic Goods Administration (TGA). But this… read more →
Recent Comments